Trial Outcomes & Findings for A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide (NCT NCT04081337)

NCT ID: NCT04081337

Last Updated: 2024-02-08

Results Overview

SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

55 participants

Primary outcome timeframe

Baseline, Week 18

Results posted on

2024-02-08

Participant Flow

Participant milestones

Participant milestones
Measure
Placebo
Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
15 Milligram (mg) Tirzepatide
Participants received 15 mg of tirzepatide QW by SC injection.
Overall Study
STARTED
28
27
Overall Study
Received at Least One Dose of Study Drug
28
27
Overall Study
COMPLETED
24
24
Overall Study
NOT COMPLETED
4
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Placebo
Participants received placebo once weekly (QW) by Subcutaneous (SC) injection.
15 Milligram (mg) Tirzepatide
Participants received 15 mg of tirzepatide QW by SC injection.
Overall Study
Adverse Event
0
1
Overall Study
Withdrawal by Subject
2
0
Overall Study
Physician Decision
1
2
Overall Study
Lost to Follow-up
1
0

Baseline Characteristics

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
n=28 Participants
Participants received placebo QW by SC injection.
15 mg Tirzepatide
n=27 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Total
n=55 Participants
Total of all reporting groups
Age, Continuous
48.1 years
STANDARD_DEVIATION 10.7 • n=39 Participants
45.5 years
STANDARD_DEVIATION 9.8 • n=41 Participants
46.8 years
STANDARD_DEVIATION 10.3 • n=35 Participants
Sex: Female, Male
Female
24 Participants
n=39 Participants
22 Participants
n=41 Participants
46 Participants
n=35 Participants
Sex: Female, Male
Male
4 Participants
n=39 Participants
5 Participants
n=41 Participants
9 Participants
n=35 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Asian
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Black or African American
12 Participants
n=39 Participants
11 Participants
n=41 Participants
23 Participants
n=35 Participants
Race (NIH/OMB)
White
15 Participants
n=39 Participants
14 Participants
n=41 Participants
29 Participants
n=35 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=39 Participants
2 Participants
n=41 Participants
3 Participants
n=35 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Region of Enrollment
United States
28 Participants
n=39 Participants
27 Participants
n=41 Participants
55 Participants
n=35 Participants

PRIMARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and had evaluable data for SMR.

SMR was measured using whole-room indirect calorimetry (respiratory chamber). Change from Baseline to Week 18 in SMR was evaluated. Least square (LS) mean was determined by analysis of covariance (ANCOVA) model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=21 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
-134.68 kilocalories per day (kcal/day)
Standard Error 21.62
-154.36 kilocalories per day (kcal/day)
Standard Error 19.69

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and had evaluable data for food Intake during ad libitum meal.

Ad libitum lunch and dinner were provided. The sum of the caloric breakdown (carbohydrates, protein, and fats) was calculated from the respective nutritional information of the food items. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=24 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Food Intake During Ad Libitum Meal
-914.51 kilocalories (kcal)
Standard Error 82.29
-58.57 kilocalories (kcal)
Standard Error 82.29

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for 24-hour EE.

24 hour energy expenditure was measured in a respiratory chamber. LS mean was determined by ANCOVA model with Baseline, Treatment, Change from Baseline to Week 18 in Fat-Free Mass, Change from baseline to Week 18 in Fat Mass and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=21 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in 24-hour Energy Expenditure (EE)
-300.07 kcal/day
Standard Error 30.44
-296.85 kcal/day
Standard Error 27.67

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for 24-hour RQ.

Respiratory quotient was calculated as the ratio of carbon dioxide production to oxygen consumption as measured in a metabolic chamber for 24 continuous hours. Ratio of total carbon dioxide production (VCO2)/total oxygen consumption (VO2), from baseline to Week 18 was evaluated. 24-hour RQ = total VCO2 \[Liter/24hour\] / total VO2 \[Liter/24hour\]. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=21 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in 24 Hour Respiratory Quotient (RQ)
-0.030 Ratio
Standard Error 0.006
0.005 Ratio
Standard Error 0.005

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for sleep RQ.

Sleep RQ is defined as the ratio of VCO2 to VO2 during sleep time points. Change from baseline to Week 18 in sleep RQ is presented. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=21 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Sleep RQ
-0,028 ratio
Standard Error 0.006
-0.001 ratio
Standard Error 0.006

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for duration of periods with RQ\<0.80.

RQ\<0.80 is defined as the cut point for high lipid oxidation of RQ; lipid oxidation will be calculated and corrected for protein oxidation; the total number of minutes with RQ \<0.80, termed "lipid oxidation duration," during each 23-hour measurement period will be recorded; protein oxidation will be determined from urine nitrogen that will be collected during 2 periods for each calorimeter day. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=21 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Duration of Periods With RQ<0.80
254.44 minute
Standard Error 47.14
2.55 minute
Standard Error 43.97

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for fat, protein, and carbohydrate oxidation.

Change from Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation is presented. * Protein Oxidation = 6.25\*\[urinary nitrogen\] * Fat Oxidation = 1.689\*\[total oxygen consumption (VO2)\] - 1.689\*\[total carbon dioxide production (VCO2)\] - 0.324\*\[protein oxidation\] * Carbohydrate Oxidation = 4.113\*\[VCO2\] - 2.907\*\[VO2\] - 0.375\*\[protein oxidation\]. Adjusted oxidation is calculated using the formula, Adjusted oxidation rate (g/day) = oxidation rate (g/day) / 24-hour Energy Expenditure) x 1000 (kcal/day). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=21 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation
Adjusted protein oxidation
-7.00 gram/day
Standard Error 1.32
-0.14 gram/day
Standard Error 1.23
Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation
Adjusted fat oxidation
12.83 gram/day
Standard Error 2.30
-1.64 gram/day
Standard Error 2.15
Change From Baseline to Week 18 in Fat, Protein, and Carbohydrate Oxidation
Adjusted carbohydrate oxidation
-22.42 gram/day
Standard Error 4.54
4.23 gram/day
Standard Error 4.24

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for body weight.

Change from baseline in BW through Week 18 in participants were presented. LS mean was determined by mixed measures repeated model (MMRM) model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=24 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=25 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Body Weight (BW)
-16.73 kilogram (kg)
Standard Error 0.92
-8.26 kilogram (kg)
Standard Error 0.90

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for body fat-free mass.

Change from baseline to Week 18 in body fat free mass is presented. Body fat free mass was measured using dual energy X-ray absorptiometry (DXA) measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=24 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Body Fat-Free Mass
-5.73 kg
Standard Error 0.36
-1.64 kg
Standard Error 0.36

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for body fat mass.

Change from baseline to Week 18 in body fat mass is presented. Body fat mass was measured using DXA measurements. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=24 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Body Fat Mass
-11.83 kg
Standard Error 0.65
-6.75 kg
Standard Error 0.65

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for percentage of body fat mass.

The total body fat mass was measured in kilograms (kg) using DXA scanning. Change from baseline to week 18 in percentage of body fat mass is reported. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=24 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Percentage of Body Fat Mass
-4.26 Percentage
Standard Error 0.36
-3.12 Percentage
Standard Error 0.36

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and who had evaluable data for lipid metabolism parameters.

Change in Lipid Metabolism Parameters from baseline (week 0) to week 18 is evaluated. Triglyceride, Very low density lipoprotein (VLDL), High density lipoprotein (HDL) cholesterol and free fatty acids values were reported. Results below presents Area under the Curve (AUC) during standardized mixed-meal tolerance test (sMMTT). LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=23 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=23 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Lipid Metabolism Parameters
Triglyceride
-2.52 millimole hour per liter (mmol.h/L)
Standard Error 0.27
-0.69 millimole hour per liter (mmol.h/L)
Standard Error 0.27
Change From Baseline to Week 18 in Lipid Metabolism Parameters
VLDL cholesterol
-1.16 millimole hour per liter (mmol.h/L)
Standard Error 0.12
-0.32 millimole hour per liter (mmol.h/L)
Standard Error 0.12
Change From Baseline to Week 18 in Lipid Metabolism Parameters
HDL cholesterol
-0.33 millimole hour per liter (mmol.h/L)
Standard Error 0.18
0.20 millimole hour per liter (mmol.h/L)
Standard Error 0.18
Change From Baseline to Week 18 in Lipid Metabolism Parameters
Free fatty acid
0.35 millimole hour per liter (mmol.h/L)
Standard Error 0.08
-0.09 millimole hour per liter (mmol.h/L)
Standard Error 0.08

SECONDARY outcome

Timeframe: Baseline, Week 18 during standardized mixed meal tolerance test

Population: All randomized participants who received at least one dose of study drug and who had evaluable HOMA-IR data.

Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a test that uses a simultaneous fasting blood glucose test and fasting insulin test to accurately estimate the degree of insulin resistance (IR) and β-cell function (the cells of the pancreas that produce insulin). HOMA-IR= \[Fasting glucose (mmol/L) x (fasting insulin (picomoles per liter {pmol/L})/6)\] / 22.5. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=19 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=23 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Fasting Insulin Resistance
-0.34 index
Standard Error 0.14
-0.37 index
Standard Error 0.12

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and had evaluable data for matsuda index.

Insulin sensitivity was measured from insulin and glucose levels obtained following standard meal challenge using a modification of the Matsuda index. This was calculated based on data obtained from a 75 g oral glucose tolerance test, as follows: 10,000 divided by the square root of {(fasting glucose X fasting insulin) (total area under the glucose response curve (AUC) 0-4hr)) X total insulin AUC(0-4hr )}. A Matsuda index of \<2.5 indicates whole body insulin resistance. A lower Matsuda Index indicates the worst disease state. An increase in the Matsuda Index indicates an improvement in insulin sensitivity (best). A positive change from Baseline indicates improvement and a negative change from Baseline indicates a worsening. Stumvoll and oral glucose insulin sensitivity indexes were also used for measuring the insulin Sensitivity. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=23 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=23 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Postprandial Insulin Sensitivity
4.92 index
Standard Deviation 0.94
1.43 index
Standard Deviation 0.94

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and had evaluable data for postmeal total glucose AUC during sMMTT.

Total AUC from time zero to 4 hours after start of the meal \[AUC0-4 hours\]) during sMMTT was evaluated. LS mean was determined by ANCOVA model with Baseline, Treatment and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=23 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=23 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Postmeal Total Glucose AUC During sMMTT
-3.00 millimolar.hour per liter (mmol.h/L)
Standard Error 0.38
-1.73 millimolar.hour per liter (mmol.h/L)
Standard Error 0.38

SECONDARY outcome

Timeframe: Baseline, Week 18

Population: All randomized participants who received at least one dose of study drug and had evaluable data for HbA1c.

HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model with Baseline, Treatment, Time, Treatment\*Time, Participant and Random Error as variables.

Outcome measures

Outcome measures
Measure
15 mg Tirzepatide
n=24 Participants
Participants received 15 mg of tirzepatide QW by SC injection.
Placebo
n=24 Participants
Participants received placebo QW by SC injection.
Change From Baseline to Week 18 in Hemoglobin A1c (HbA1c)
-0.40 percentage of glycosylated hemoglobin
Standard Error 0.04
-0.04 percentage of glycosylated hemoglobin
Standard Error 0.04

Adverse Events

Placebo

Serious events: 0 serious events
Other events: 19 other events
Deaths: 0 deaths

15 mg Tirzepatide

Serious events: 1 serious events
Other events: 22 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Placebo
n=28 participants at risk
Participants received placebo once weekly by SC injection.
15 mg Tirzepatide
n=27 participants at risk
Participants received 15 mg of tirzepatide once weekly by subcutaneous injection.
Gastrointestinal disorders
Pancreatitis
0.00%
0/28 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
3.7%
1/27 • Number of events 1 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Hepatobiliary disorders
Cholelithiasis
0.00%
0/28 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
3.7%
1/27 • Number of events 1 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.

Other adverse events

Other adverse events
Measure
Placebo
n=28 participants at risk
Participants received placebo once weekly by SC injection.
15 mg Tirzepatide
n=27 participants at risk
Participants received 15 mg of tirzepatide once weekly by subcutaneous injection.
Gastrointestinal disorders
Abdominal discomfort
7.1%
2/28 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
0.00%
0/27 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Gastrointestinal disorders
Abdominal distension
3.6%
1/28 • Number of events 3 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
11.1%
3/27 • Number of events 8 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Gastrointestinal disorders
Abdominal pain
0.00%
0/28 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
7.4%
2/27 • Number of events 3 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Gastrointestinal disorders
Abdominal pain upper
3.6%
1/28 • Number of events 1 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
7.4%
2/27 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Gastrointestinal disorders
Constipation
14.3%
4/28 • Number of events 9 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
37.0%
10/27 • Number of events 11 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Gastrointestinal disorders
Diarrhoea
7.1%
2/28 • Number of events 3 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
22.2%
6/27 • Number of events 6 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Gastrointestinal disorders
Dyspepsia
0.00%
0/28 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
18.5%
5/27 • Number of events 5 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Gastrointestinal disorders
Flatulence
7.1%
2/28 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
0.00%
0/27 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Gastrointestinal disorders
Nausea
25.0%
7/28 • Number of events 8 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
51.9%
14/27 • Number of events 29 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Gastrointestinal disorders
Vomiting
10.7%
3/28 • Number of events 4 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
25.9%
7/27 • Number of events 8 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
General disorders
Injection site reaction
0.00%
0/28 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
37.0%
10/27 • Number of events 31 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
General disorders
Pain
7.1%
2/28 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
0.00%
0/27 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Infections and infestations
Corona virus infection
14.3%
4/28 • Number of events 4 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
3.7%
1/27 • Number of events 1 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Infections and infestations
Sinusitis
7.1%
2/28 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
0.00%
0/27 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Infections and infestations
Urinary tract infection
10.7%
3/28 • Number of events 3 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
7.4%
2/27 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Musculoskeletal and connective tissue disorders
Back pain
7.1%
2/28 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
0.00%
0/27 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Nervous system disorders
Dizziness
7.1%
2/28 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
3.7%
1/27 • Number of events 1 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Nervous system disorders
Headache
32.1%
9/28 • Number of events 10 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
22.2%
6/27 • Number of events 6 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Reproductive system and breast disorders
Metrorrhagia
0.00%
0/24 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
9.1%
2/22 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
Respiratory, thoracic and mediastinal disorders
Sinus congestion
7.1%
2/28 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.
7.4%
2/27 • Number of events 2 • Baseline Through End of Safety Follow-up (Up to 22 Weeks)
All randomized participants who received at least one dose of study drug, regardless of whether they completed all protocol requirements. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly. Frequency threshold for reporting other (not including serious) adverse event is greater than or equal to (≥) 5% in any of the treatment groups.

Additional Information

Chief Medical Officer

Eli Lilly and Company

Phone: 800-545-5979

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60